Novartis Fabhalta (iptacopan) Receives FDA Traditional Approval as First and Only Complement Inhibitor to Significantly Slow Kidney Function Decline in Primary IgAN
RegulatoryapprovedFabhaltaPositive
AI Analysis
Summary
Novartis announced FDA traditional approval of Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgAN, marking the first and only complement inhibitor approved for this indication. This represents a significant regulatory milestone for the treatment of this rare kidney disease.
Outcome Details
FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Importance:9/10
Sentiment:
0.90
FDA approvalfirst-in-classcomplement inhibitorkidney diseaseIgANregulatory milestone
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 17, 2026 8:07 PM